Size | Price | Stock | Qty |
---|---|---|---|
50mg |
|
||
100mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
Other Sizes |
|
Purity: ≥98%
Metoprolol Tartrate (CGP2175E; CGP-2175E; Lanoc; Lopressor; Metomerck; Metop; Selopral; Ritmolol), the tartrate salt of Metoprolol, is a potent and cardioselective β1 receptor blocker with antihypertensive effects. It is a medication for high blood pressure and heart failure.
Targets |
β-adrenergic receptor
|
---|---|
ln Vitro |
Metoprolol (0-1000 μg/mL; 24-72 h) exhibits dose- and time-dependent cytotoxicity on MOLT-4 and U937 cells[3].
|
ln Vivo |
Metoprolol (2.5 mg/kg/h; infusion; 11 weeks) decreases atherosclerosis and proinflammatory cytokines in ApoE-/- mice[1].
Metoprolol (15 mg/kg/q12h; i.e., 5 days) exhibits anti-viral and anti-inflammatory properties in a murine model of viral myocarditis caused by the coxsackievirus B3[2]. Metoprolol (2.5 mg/kg; intravenously; three bolus injections) inhibits myocardial apoptosis and significantly reduces the expression of activated caspase-9 protein in coronary microembolization (CME) rats[4]. |
Cell Assay |
Cell Line: U937 and MOLT-4 cells
Concentration: 1, 10, 50, 100, 500 and 1000 μg/mL Incubation Time: 24, 48 and 72 h Result: Significantly reduced the viability of MOLT-4 and U937 cells at 1000 μg/mL (3740.14µM) concentration after 48 hours of incubation; similarly, after 72 hours, the viability of MOLT4 cells at ≥100 μg/ml (≥374.01µM) concentrations and U937 cells at ≥500 μg/ml (≥1870.07µM) concentrations was observed. |
Animal Protocol |
Male ApoE-/- mice
2.5 mg/kg/h Via osmotic minipumps, 11 weeks |
References |
Molecular Formula |
C34H56N2O12
|
|
---|---|---|
Molecular Weight |
684.81
|
|
Exact Mass |
684.38
|
|
Elemental Analysis |
C, 59.63; H, 8.24; N, 4.09; O, 28.03
|
|
CAS # |
56392-17-7
|
|
Related CAS # |
Metoprolol; 51384-51-1; Metoprolol succinate; 98418-47-4; Metoprolol-d7 hydrochloride; 1219798-61-4; Metoprolol-d6 tartrate
|
|
Appearance |
White to off-white crystalline powder
|
|
SMILES |
CC(C)NCC(COC1=CC=C(C=C1)CCOC)O.CC(C)NCC(COC1=CC=C(C=C1)CCOC)O.C(C(C(=O)O)O)(C(=O)O)O
|
|
InChi Key |
YGULWPYYGQCFMP-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/2C15H25NO3.C4H6O6/c2*1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3;5-1(3(7)8)2(6)4(9)10/h2*4-7,12,14,16-17H,8-11H2,1-3H3;1-2,5-6H,(H,7,8)(H,9,10)
|
|
Chemical Name |
2,3-dihydroxybutanedioic acid;1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.4603 mL | 7.3013 mL | 14.6026 mL | |
5 mM | 0.2921 mL | 1.4603 mL | 2.9205 mL | |
10 mM | 0.1460 mL | 0.7301 mL | 1.4603 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT02123056 | Active Recruiting |
Drug: Metoprolol Drug: Matching Placebo |
Vasovagal Syncope | University of Calgary | October 2014 | Phase 4 |
NCT01608893 | Active Recruiting |
Drug: Carvedilol Drug: Metoprolol |
Atrial Fibrillation | University of Calgary | May 2012 | Not Applicable |
NCT03278509 | Active Recruiting |
Drug: Metoprolol Succinate Drug: Bisoprolol |
Acute Myocardial InfarctionST Elevation Myocardial Infarction |
Karolinska Institutet | September 11, 2017 | Phase 4 |
NCT03070184 | Active Recruiting |
Other: Exercise challenge Drug: Metoprolol Succinate ER |
Healthy Pre Hypertension |
University of Alabama at Birmingham |
April 30, 2017 | Phase 2 |
NCT05741385 | Recruiting | Drug: Caffeine Drug: Warfarin sodium Drug: Omeprazole Drug: Metoprolol |
Liver Cirrhosis | Boehringer Ingelheim | April 25, 2023 | Not Applicable |
Metoprolol dose-finding (Study I). (a) 24-hour heart rate during baseline conditions after three different doses of metoprolol compared with Control mice. Biomed Res Int . 2014:2014:548783 td> |
Metoprolol decreases atherosclerosis. Biomed Res Int . 2014:2014:548783. td> |
Photomicrographs showing the effect of metoprolol on apoptosis following coronary microembolization (original magnification ×400). Exp Clin Cardiol . 2013 Spring;18(2):161-5. td> |
Graph showing the effect of metoprolol on apoptosis following coronary microembolization (CME). Exp Clin Cardiol . 2013 Spring;18(2):161-5. td> |